MX2020002692A - Formulacion de resiniferatoxina. - Google Patents

Formulacion de resiniferatoxina.

Info

Publication number
MX2020002692A
MX2020002692A MX2020002692A MX2020002692A MX2020002692A MX 2020002692 A MX2020002692 A MX 2020002692A MX 2020002692 A MX2020002692 A MX 2020002692A MX 2020002692 A MX2020002692 A MX 2020002692A MX 2020002692 A MX2020002692 A MX 2020002692A
Authority
MX
Mexico
Prior art keywords
rtx
resiniferatoxin
disclosed
formulation
formulations
Prior art date
Application number
MX2020002692A
Other languages
English (en)
Inventor
Bryan Jones
Alexis Nahama
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of MX2020002692A publication Critical patent/MX2020002692A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Abstract

En la presente se describen formulaciones más seguras de resiniferatoxina (RTX) para administración intratecal, intraganglionar, intraarticular y pericardial. Más específicamente, se describen formulaciones de RTX sin alcohol que comprenden un componente solubilizante, un monosacárido o alcohol de azúcar, una solución salina amortiguadora y RTX y que tiene rangos estrechos para el rango de pH y gravedad específica.
MX2020002692A 2017-09-11 2018-09-11 Formulacion de resiniferatoxina. MX2020002692A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762556824P 2017-09-11 2017-09-11
PCT/IB2018/056944 WO2019049112A1 (en) 2017-09-11 2018-09-11 RESINIFERATOXIN FORMULATION

Publications (1)

Publication Number Publication Date
MX2020002692A true MX2020002692A (es) 2020-10-14

Family

ID=63708422

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002692A MX2020002692A (es) 2017-09-11 2018-09-11 Formulacion de resiniferatoxina.
MX2022013947A MX2022013947A (es) 2017-09-11 2020-03-10 Formulacion de resiniferatoxina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022013947A MX2022013947A (es) 2017-09-11 2020-03-10 Formulacion de resiniferatoxina.

Country Status (9)

Country Link
US (2) US20190076396A1 (es)
EP (1) EP3681472A1 (es)
JP (2) JP7358337B2 (es)
KR (1) KR20200051771A (es)
CN (1) CN111315360A (es)
AU (1) AU2018327301A1 (es)
CA (1) CA3074951A1 (es)
MX (2) MX2020002692A (es)
WO (1) WO2019049112A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11447444B1 (en) 2019-01-18 2022-09-20 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11254659B1 (en) 2019-01-18 2022-02-22 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
WO2020226370A1 (ko) 2019-05-09 2020-11-12 주식회사 엘지화학 전기화학소자용 분리막 및 이를 포함하는 전기화학소자
CN115551480A (zh) * 2020-04-15 2022-12-30 格吕伦塔尔有限公司 树脂毒素组合物
CN117120049A (zh) * 2021-02-11 2023-11-24 索伦托药业有限公司 施用树脂毒素以治疗前列腺癌

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2187193B (en) 1986-02-27 1989-11-08 Gerald Scott Controllably and swiftly degradable polymer compositions and films and other products made therefrom
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5232684A (en) 1990-06-29 1993-08-03 The United States Of America As Represented By The Department Of Health And Human Services Labelled resiniferatoxin, compositions thereof, and methods for using the same
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
JP2006513267A (ja) * 2002-12-18 2006-04-20 アルゴルクス ファーマスーティカルズ，インク カプサイシノイドの投与
MX2007006253A (es) * 2004-11-24 2007-10-18 Anesiva Inc Formulacion de gel de capsaicinoide y usos para esta.
EP1830835B1 (de) * 2004-12-28 2012-03-14 Mestex AG Verwendung eines vanilloidrezeptoragonisten zusammen mit einem glycosaminoglycan oder proteoglycan f]r die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels
CA2594202C (en) * 2004-12-28 2013-12-03 Mestex Ag Use of resiniferatoxin (rtx) for producing an agent for treating joint pains and method for applying said agent
US9956166B2 (en) * 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
CA3123222A1 (en) * 2018-12-21 2020-06-25 Sorrento Therapeutics, Inc. Perineural administration of resiniferatoxin for treatment of maladaptive pain

Also Published As

Publication number Publication date
JP7358337B2 (ja) 2023-10-10
KR20200051771A (ko) 2020-05-13
EP3681472A1 (en) 2020-07-22
US20220370405A1 (en) 2022-11-24
CN111315360A (zh) 2020-06-19
AU2018327301A1 (en) 2020-04-09
CA3074951A1 (en) 2019-03-14
JP2022176377A (ja) 2022-11-25
MX2022013947A (es) 2022-11-30
JP2020533336A (ja) 2020-11-19
US20190076396A1 (en) 2019-03-14
WO2019049112A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
MX2022013947A (es) Formulacion de resiniferatoxina.
EP4338752A3 (en) Stable liquid pharmaceutical preparation
PH12017500844B1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
NZ743964A (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
MX2019000427A (es) Formas de dosificacion oral de cannabinoide de alta concentracion.
EP4302830A3 (en) Quinazoline derivatives used to treat hiv
EP3638248A4 (en) CONJUGATES OF PHARMACEUTICAL INGREDIENTS
EA201691478A1 (ru) Новый полисахарид и его применения
MX2017007178A (es) Formulaciones liquidas estables de virus de vacuna.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
MX2017004975A (es) Composiciones de anticuerpos anti-il-7r.
MX2020010116A (es) Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk).
MX2017009759A (es) Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable.
WO2018091729A3 (en) Aqueous pharmaceutical formulations
NZ728401A (en) High purity oritavancin and method of producing same
PH12017502319A1 (en) Injectable pharmaceutical formulations of lefamulin
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
WO2019027221A3 (ko) pH 민감성 성분의 안정화용 조성물
WO2018170236A9 (en) CDPK1 INHIBITORS, COMPOSITIONS AND RELATED METHODS
EP3849307A4 (en) TWO-CHAMBER VIALS FOR PRESERVING A CORNEAL TRANSPLANT
PH12018502139A1 (en) Phosphaplatin liquid formulations
MX2022006784A (es) Formulaciones de anticuerpos anti-pd-l1.
CR20200552A (es) Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripe
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола